Trial
NCT05827614
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Boundless Bio, Inc.
Collaborators
—
Condition
Triple Negative Breast Cancer (TNBC)
Intervention
BBI-355
Why stopped
Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-08